The deal will cover the manufacturing of 10 biosimilar drugs
Sydney-based biotechnology firm, NeuClone has signed a major licensing agreement and joint development partnership with The Serum Institute of India. The deal will cover the manufacture of 10 biosimilar drugs.
As per the agreement, NeuClone will use its NeuMAX cell line development platform to manufacture and supply ten biosimilar monoclonal antibody drugs.
One of the world's largest vaccine producer, The Serum Institute, will provide its biologics manufacturing capability.
The companies explained that the drugs will target cancer and autoimmune disorders, and each will address markets worth hundreds of millions to billions of dollars.
As part of the partnership, NeuClone will retain the licence to the biosimilars for the markets of the US, Europe, Canada, Australia, Taiwan, Japan and South Korea.